Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017:331:1-53.
doi: 10.1016/bs.ircmb.2016.09.008. Epub 2016 Dec 2.

Breast Cancer Immunology and Immunotherapy: Current Status and Future Perspectives

L de la Cruz-Merino  1 , M Chiesa  2 , R Caballero  2 , F Rojo  3 , N Palazón  2 , F H Carrasco  2 , V Sánchez-Margalet  4
Affiliations
Review

Breast Cancer Immunology and Immunotherapy: Current Status and Future Perspectives

L de la Cruz-Merino et al. Int Rev Cell Mol Biol. 2017.

Abstract

Cancer immunology has gained renewed interest in the past few years due to emerging findings on mechanisms involved in tumoral immune evasion. Indisputably, immune edition is currently considered a critical hallmark of cancer. Basic research has revealed new targets which can be modulated in the clinical setting with new compounds and strategies. As recent evidence confirms, breast cancer (BC) is a complex and heterogeneous disease in which host immune responses play a substantial role. T-infiltrating lymphocytes measurement is suggested as a powerful new tool necessary to predict early BC evolution, especially in HER2-positive and triple negative subtypes. However, T-infiltrating lymphocytes, genomic platforms, and many other biomarkers in tissue and peripheral blood (e.g., regulatory T cells and myeloid-derived suppressor cells) are not the only factors being evaluated regarding their potential role as prognostic and/or predictive factors. Many ongoing clinical trials are exploring the activity of immune checkpoint modulators in BC treatment, both in the advanced and neoadjuvant setting. Although this field is expanding with exciting new discoveries and promising clinical results-and creating great expectations-there remain many uncertainties yet to be addressed satisfactorily before this long awaited therapeutic promise can come to fruition.

Keywords: Breast cancer; Clinical trial; Immune checkpoints; Immunogenic cell death; Immunotherapy; Myeloid-derived suppressor cells; Neoantigens; Regulatory T-cells; Tumor-infiltrating lymphocytes.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

LinkOut - more resources